NewAmsterdam Pharma Company NAMS Prepaid & Other Current
Prepaid & Other Current at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's prepaid & other current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's prepaid & other current?
- NewAmsterdam Pharma Company (NAMS) reported prepaid & other current of $20.6M in Q1 2026.
- How has NewAmsterdam Pharma Company's prepaid & other current changed year-over-year?
- NewAmsterdam Pharma Company's prepaid & other current increased by 133.4% year-over-year, from $8.83M to $20.6M.
- What is the long-term trend for NewAmsterdam Pharma Company's prepaid & other current?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's prepaid & other current has grown at a 55.0% compound annual growth rate (CAGR), from $10.25M to $38.14M.
- What does prepaid & other current mean?
- Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.